This inventor holds 3 USPTO granted patents. Top assignees: Dartmouth College, University of Massachusetts. Active years: 1997-2009.
Company Filing History:


Years Active: 1997-2009
Title: Dale L Grenier: Innovator in T-Cell Tolerance and Transplantation
Introduction
Dale L Grenier is a notable inventor based in Hubbardston, MA (US). He has made significant contributions to the field of immunology, particularly in methods related to T-cell tolerance and transplantation. With a total of 3 patents, his work has the potential to impact various medical treatments and transplant procedures.
Latest Patents
Grenier's latest patents focus on innovative methods for inducing T-cell non-responsiveness and tolerance in transplant recipients. One of his key inventions involves administering allogeneic or xenogeneic cells that express donor antigens, along with an antagonist that inhibits the interaction of a receptor on recipient T cells. This method aims to facilitate the acceptance of transplanted tissues or organs, such as liver, kidney, heart, lung, skin, muscle, neuronal tissue, stomach, and intestine. Additionally, he has developed methods for treating diabetes by administering specific cells and antagonists to enhance tolerance.
Career Highlights
Throughout his career, Dale L Grenier has worked with prestigious institutions, including Dartmouth College and the University of Massachusetts. His research has contributed to advancements in the understanding of immune responses and transplant acceptance, making him a valuable figure in the field of medical research.
Collaborations
Grenier has collaborated with notable colleagues, including Randolph J Noelle and Fiona H Durie. These partnerships have likely enriched his research and expanded the impact of his innovations in immunology.
Conclusion
Dale L Grenier's work in T-cell tolerance and transplantation represents a significant advancement in medical science. His innovative methods have the potential to improve transplant success rates and offer new treatment options for patients.